MACQUARIE UNIVERSITY
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Private
- Established
- 1964-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- https://www.mq.edu.au
Clinical Trials
147
Active:5
Completed:59
Trial Phases
5 Phases
Phase 1:2
Phase 2:6
Phase 3:2
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (141 trials with phase data)• Click on a phase to view related trials
Not Applicable
126 (89.4%)Phase 2
6 (4.3%)Phase 4
5 (3.5%)Phase 1
2 (1.4%)Phase 3
2 (1.4%)No trials found
News
Tofersen Shows Promise in Slowing Progression of SOD1 Motor Neuron Disease
Tofersen, developed by Biogen, has demonstrated significant efficacy in slowing the progression of MND in patients with the SOD1 genetic mutation, offering a breakthrough in treatment for this previously untreatable condition.
Dual-Drug Combination Shows Promise for Dementia with Lewy Bodies
A Phase II clinical trial is underway at Macquarie University, combining doxycycline and ambroxol to combat Dementia with Lewy Bodies (DLB).